Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Docta Complutense
Publicación Artículo científico (JournalArticle)

Pulmonary surfactant nanoparticles for lung‐targeted and dose‐efficient delivery

  • Fernández Méndez, Laura
  • Piñol Cancer, Marina
  • Souto Riobó, Itziar
  • Urkola Arsuaga, Ainhize
  • González Lozano, Elena
  • Fernández Folgueral, Irene
  • de Alejo, Claudia Miranda Pérez
  • Azkargorta, Mikel
  • Elortza, Felix
  • Tagliaferro Quiñonero, Alberto
  • Silvio, Desire Di
  • Cañadas Benito, Olga
  • Maiz, Jon
  • Pérez Gil, Jesús
  • Ramos Cabrer, Pedro
  • Ruíz Cabello, Jesús
  • Carregal Romero, Susana
Although pulmonary drug delivery enables lung-targeted therapy, its clinical efficacy is often limited by inflammation, heterogeneous deposition, and physiological barriers such as mucociliary clearance and phagocytic uptake. Here, we report a biomimetic platform based on pulmonary surfactant nanoparticles (PSNPs) that preserves native surfactant proteins and biophysical functionality, resulting in enhanced pulmonary delivery. Microfluidic synthesis yielded highly uniform PSNPs with improved encapsulation efficiency and colloidal stability, while markedly increasing surfactant protein retention from 33% using conventional extrusion to 95% via microfluidics, corresponding to a 2.4-fold improvement. Functionally, PSNPs exhibited superior interfacial activity compared to lipid-only liposomes, increasing surface pressure from 5–10 mN/m to 25–30 mN/m, and achieved an approximately 80-fold enhancement in alveolar cellular uptake. In vitro, nintedanib-loaded PSNPs significantly reduced fibroblast migration, proliferation, collagen deposition, and TGF-β secretion relative to free drug and control formulations. In vivo, PSNPs demonstrated high pulmonary retention (95% injected dose per gram of lung tissue), efficient penetration into fibrotic regions, and minimal off-target accumulation in the liver (0.5%). Therapeutic efficacy was confirmed in a bleomycin-induced pulmonary fibrosis model, where PSNPs improved lung function and restored tissue architecture at doses as low as 0.5 mg/kg. Collectively, these results establish PSNPs as a robust lung-targeted nanotherapeutic platform, where microfluidic synthesis enables enhanced biomimicry, improved protein preservation, and superior therapeutic performance compared to conventional fabrication methods.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

NIR-II Photoresponsive magnetoliposomes for remote-controlled release and magnetic resonance imaging

  • Fernández-Méndez, Laura
  • Fernández-Afonso, Yilian
  • Martínez-Vicente, Pablo
  • Urkola-Arsuaga, Ainhize
  • Miranda-Pérez de Alejo, Claudia
  • Pisa, Irati L. de la
  • Plaza-García, Sandra
  • Ruíz-Cabello, Jesús
  • Ramos-Cabrer, Pedro
  • Gutiérrez, Lucía
  • Carregal-Romero, Susana
Magnetic nanoparticles, especially iron oxide nanoparticles, have become versatile and widely used tools in nanomedicine due to their unique magnetic properties, biocompatibility, and tunable functionality. Liposomes have further enhanced the potential of iron oxide nanoparticles by serving as effective nanocarriers with advantages such as drug coencapsulation and enhanced molecular imaging properties. In this study, we present magnetoliposomes composed of ultrasmall free-floating iron oxide nanoparticles inside liposomes (LP-IONPs) and thermoresponsive phospholipids, which were designed as dual T2-T1 magnetic resonance imaging (MRI) contrast agents for image-guided liposome degradation and infrared light-responsive nanocarriers in the second biological window for remote-controlled drug delivery. We demonstrated a dynamic shift from T2 to T1 MRI contrast during intracellular degradation of LP-IONPs, along with successful light-activated drug release in cancer cells. Biodistribution studies using MRI and histological analysis confirmed their potential for in vivo applications. These results highlight the potential of LP-IONPs as image-guided and remote-controlled drug delivery systems., S.C.R. thanks the MCIN/AEI 10.13039/501100011033 projects (PID2019-106139RA-100, CNS2023-143944, RYC2020-030241-I, and PID2022-142842OB-I00), the Ikerbasque (Basque Foundation for Science), and the Ramón Areces Foundation (CIVP21S13151). J.R.C. is funded by MCIN/AEI/10.13039/501100011033 (PID2021-123238OB-I00), the Basque Government through the Elkartek 2024 program (bmG24), and R&D projects in Health (grant number 2022333041). S.C.R. and J.R.C. thank IKERBASQUE for its support. L.G. thanks Project CNS2023-144321, funded by MICIU/AEI/10.13039/501100011033 and NextGenerationEU/PRT, and Fondo Social del Gobierno de Aragón (grupo DGA E15-23R). We also thank the Fundación contra la Hipertensión Pulmonar for funding (Empathy). CIBERES and CIBERBBN were co-funded by FEDER and ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Iron Oxide Nanoparticles for Ligand-Mediated Targeted Imaging

  • Miranda-Pérez de Alejo, Claudia
  • Miguel-Coello, Ana B.
  • Piñol-Cancer, Marina
  • Urkola-Arsuaga, Ainhize
  • Martínez-Parra, Lydia
  • Carrillo-Romero, Juliana
  • Fernández-Méndez, Laura
  • Goñi-de-Cerio, Felipe
  • Herranz, Fernando
  • Silvio, Desire di
  • Gallego, Marta
  • Sierra-Serrano, Beatriz
  • Cardo, Lucia
  • Carregal-Romero, Susana
  • Ruiz-Cabello, Jesús
Superparamagnetic iron oxide nanoparticles (SPIONs) are widely employed as platforms for ligand-mediated targeting in multimodal imaging and targeted therapeutic applications owing to their intrinsic magnetic properties and versatility for surface and core modification. In addition to magnetic resonance imaging contrast, SPIONs can be labeled with radioisotopes incorporated into the crystalline structure or functionalized with chemically bound dyes or chelating agents, enabling complementary imaging modalities such as fluorescence imaging and positron emission tomography. However, chemical functionalization of nanoparticles with targeting ligands can induce alterations not only in their physicochemical properties but also in their interactions with biological systems. These nano-biointeractions are critical determinants of biological performance and must be carefully evaluated. In this study, we investigate the impact of ligand functionalization on SPION-cancer cell interactions to elucidate key parameters relevant to the successful clinical translation of nanomedicine-based targeted imaging agents., SCR acknowledges the Ramón Areces Foundation (CIVP21S13151),the MCIN/AEI 10.13039/501100011033 projects (PID2022-142842OB-I00,CNS2023-143944, RYC2020-030241-I), the Eusko Jaurlaritza projects(PIBA_2025_1_0057) and the Diputación Foral de Gipuzkoa (2025-CIE4-000041-01). JRC is funded by the MCIN/AEI/10.13039/501100011033(PID2021-123238OB-I00 and PID2024-155807OB-C21), the Eusko Jaurlar-itza under the Elkartek 2024 and 2025 Programs (KK-2024-00041, bmG24,and KK-20205-00084, TERACARD, respectively), and R&D projects in Health (Grant number 2022333041). SCR and JRC thank IKERBASQUE for their sponsorships. We also acknowledge the “Fundación contra la hipertensión pulmonar” for funding (Empathy)., Peer reviewed
Docta Complutense
Publicación Artículo científico (JournalArticle)

The role of PEGylation in the pulmonary delivery of antifibrotic liposomal therapies

  • Piñol Cancer, Marina
  • Fernández Méndez, Laura
  • Carrillo Romero, Juliana
  • Urkola Arsuaga, Ainhize
  • Azkargorta, Mikel
  • Elortza, Félix
  • Goñi de Cerio, Felipe
  • García Mouton, Cristina
  • Miranda-Pérez de Alejo, Claudia
  • Ismalaj, Ermal
  • Cañadas Benito, Olga
  • Pérez Gil, Jesús
  • Ruiz-Cabello Osuna, Jesús
  • Carregal Romero, Susana
PEGylation is commonly used to improve the pharmacokinetics and efficacy of intravenously administered drug nanocarriers; however its impact on pulmonary drug delivery remains unclear. While previous studies have focused on its role in crossing the lung mucosal barrier and stabilizing formulations for nebulization, less is known about its effects on lung surfactant corona composition, biodistribution, and therapeutic efficacy. Here, we present a multiscale study on how PEG-free and PEGylated liposomes loaded with pirfenidone interact with pulmonary barriers. PEGylation increased mucus penetration and reduced protein adsorption in the lung surfactant corona. However, statistical analysis of functional proteins showed only moderate changes in anti-inflammatory and adhesion proteins, with no apparent effect on key surfactant proteins that influence liposome fate in the lung. This correlated with similar biodistributions and retention times in both healthy and fibrotic lungs for PEG-free and PEGylated liposomes. Concerningly, PEGylated liposomes enhanced native surfactant fluidity, potentially altering lung function. In a bleomycin-induced pulmonary fibrosis model, both PEG-free and PEGylated liposomes improved the antifibrotic efficacy of pirfenidone. However, PEGylation attenuated the reduction in fibrotic biomarkers within the lung fluid. These findings suggest that, although PEGylation facilitates mucus penetration, it does not significantly enhance therapeutic outcomes and may adversely affect lung function. This study provides critical insights into the optimization of lipid-based nanocarriers for pulmonary fibrosis and other lung diseases.
Docta Complutense
Publicación Artículo científico (JournalArticle)

Einstein-Maxwell-scalar black holes: the hot, the cold and the bald

  • Blázquez Salcedo, José Luis
  • Herdeiro, Carlos A.R.
  • Kunz, Jutta
  • Pombo, Alexandre M.
  • Radu, Eugen
The phenomenon of spontaneous scalarisation of charged black holes (BHs) has recently motivated studies of various Einstein-Maxwell-scalar models. Within these models, different classes of BH solutions are possible, depending on the non-minimal coupling function f(φ), between the scalar field and the Maxwell invariant. Here we consider the class wherein both the (bald) electrovacuum Reissner-Nordström (RN) BH and new scalarised BHs co-exist, and the former are never unstable against scalar perturbations. In particular we examine the model, within this subclass, with a quartic coupling function: f(φ) =1 +α(φ)4. The domain of existence of the scalarised BHs, for fixed α, is composed of two branches. The first branch (coldscalarised BHs) is continuously connected to the extremal RN BH. The second branch (hotscalarised BHs) connects to the first one at the minimum value of the charge to mass ratio and it includes overcharged BHs. We then assess the perturbative stability of the scalarised solutions, focusing on spherical perturbations. On the one hand, cold scalarised BHs are shown to be unstable by explicitly computing growing modes. The instability is quenched at both endpoints of the first branch. On the other hand, hot scalarised BHs are shown to be stable by using the S-deformation method. Thus, in the spherical sector this model possesses two stable BH local ground states (RN and hot scalarised). We point out that the branch structure of BHs in this model parallels the one of BHs in five dimensional vacuum gravity, with [Myers-Perry BHs, fat rings, thin rings] playing the role of [RN, cold scalarised, hot scalarised] BHs.